Literature DB >> 11830216

Ulcerative colitis.

Richard J Farrell1, Mark A Peppercorn.   

Abstract

Ulcerative colitis is a chronic inflammatory disease of the rectum and colon. Results from many studies in people and animals of intestinal inflammation suggest that ulcerative colitis results from environmental factors triggering a loss of tolerance for normal intestinal flora in genetically susceptible individuals. Although progress has been made in the overall management of the disease, no innovative treatment has been developed. By contrast with Crohn's disease, there are few clinical data on biological agents. Probiotics seem the most promising of several experimental and traditional agents that have been investigated in controlled clinical trials.

Entities:  

Mesh:

Year:  2002        PMID: 11830216     DOI: 10.1016/S0140-6736(02)07499-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  75 in total

Review 1.  Considerations of traditional Chinese medicine as adjunct therapy in the management of ulcerative colitis.

Authors:  Chi Zhang; Miao Jiang; Aiping Lu
Journal:  Clin Rev Allergy Immunol       Date:  2013-06       Impact factor: 8.667

Review 2.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

3.  Ulcerative colitis that developed 8 years after human parvovirus B19 encephalopathy.

Authors:  Toru Watanabe
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.183

4.  Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia.

Authors:  Xiaotan Dou; Junhua Xiao; Ziliang Jin; Ping Zheng
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

5.  Target biopsy or step biopsy? Optimal surveillance for ulcerative colitis: a Japanese nationwide randomized controlled trial.

Authors:  Toshiaki Watanabe; Yoichi Ajioka; Takayuki Matsumoto; Naoki Tomotsugu; Toru Takebayashi; Eisuke Inoue; Bunei Iizuka; Masahiro Igarashi; Yasushi Iwao; Kazuo Ohtsuka; Shin-ei Kudo; Kiyonori Kobayashi; Miwa Sada; Takayuki Matsumoto; Ichiro Hirata; Kazunari Murakami; Masakazu Nagahori; Kenji Watanabe; Nobuyuki Hida; Fumiaki Ueno; Shinji Tanaka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

Review 6.  Radical induction theory of ulcerative colitis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

7.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

8.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats.

Authors:  György Rumi; Ryouichi Tsubouchi; Mitsuaki Okayama; Shinichi Kato; Gyula Mózsik; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

10.  Stress increases susceptibility to oxidative/nitrosative mucosal damage in an experimental model of colitis in rats.

Authors:  Arturo L Colón; José L M Madrigal; Luis A Menchén; María A Moro; Ignacio Lizasoain; Pedro Lorenzo; Juan C Leza
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.